03
Sep 10
Save the date: CML Update from the SPIRIT 2 team on 15 October 2010, 1-2pm.
10
Aug 10
New staff member - welcome to Lynn Seeley
02
New study reported at EHA on the search for a suitable target to potentially develop an antibody therapy in CML.
22
Jun 10
Nilotinib and dasatinib both show some improvement over imatinib with one year follow up: no long-term survival data yet.
21
May 10
The annual visits are of paramount importance to allow us to accurately measure cytogenetic and molecular treatment response.
We have 2 new eCRF pages for SPIRIT 2.
29
Mar 10
Please note our Easter Holiday arrangements
We would like to welcome Caroline to the team!
24
Dr Kaczmarski - The Hillingdon Hospital NHS Trust
Jan 10
Please take a look at the main abstracts from ASH 2009
Further details and registration forms will be available shortly, but anyone interested is invited to contact marion.mckenna@cmft.nhs.uk or call 0161-276 3360
12
ENESTnd study of up front nilotinib from ASH 2009
01
Dec 09
The provisional NICE Appraisal Consultation Document (ACD) on second-line dasatinib and nilotinib was published on 16th November and is open for comments until Monday 7th December.
Trial Secretaries
Landline: +44 191 282 0904 or 4157
Mobile:
Fax: +44 191 376 0748
Email: wendy.banks@ncl.ac.uk, meg.buckley@ncl.ac.uk
Copyright University of Newcastle | Web Design and Development by Chocolate Grape